Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia

PLoS Medicine

Volumn 3, Issue 8, 2006, Pages 1420-1428

  Holmes, Elaine ^a   Tsang, Tsz M ^a   Huang, Jeffrey T J ^b   Leweke, F Markus ^c   Koethe, Dagmar ^c   Gerth, Christoph W ^c   Nolden, Brit M ^c   Gross, Sonja ^c   Schreiber, Daniela ^c   Nicholson, Jeremy K ^a   Bahn, Sabine ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; GLUCOSE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA; TREATMENT OUTCOME; DRUG EFFECT; GLUCOSE BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE; ONSET AGE; REPRODUCIBILITY;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CEREBROSPINAL FLUID; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; GLUCOSE; HUMANS; MALE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33748354488     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030327     Document Type: Article

References (42)

1. Nicholson JK, Lindon JC, Holmes E (1999) "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
2. 1H nuclear magnetic resonance spectroscopy. Magn Reson Med 53: 1018-1024.
3. Nicholson JK, Connelly J, Lindon JC, Holmes E (2002) Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1: 153-161.
4. 1H-NMR-based metabonomics. Nat Med 8: 1439-1444.
5. Nicholson JK, Holmes E, Lindon JC, Wilson ID (2004) The challenges of modeling mammalian biocomplexity. Nat Biotechnol 22: 1268-1274.
6. 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128: 32-36.
7. 1H NMR study. NMR Biomed 18: 24-33.
8. 1H-NMR-based metabonomics. Int J Cancer 113: 782-788.
9. 1H NMR spectroscopy. J Proteome Res 5: 483-492.
10. Cheng LL, Newell K, Mallory AE, Hyman BT, Gonzalez RG (2002) Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 20: 527-533.
11. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, et al. (1997) Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 94: 6408-6413.
12. Beckwith-Hall BM, Nicholson JK, Nicholls AW, Foxall PJ, Lindon JC, et al. (1998) Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol 11: 260-272.
13. 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-Hydroxyglutaric aciduria and maple syrup urine disease. J Pharm Biomed Anal 15: 1647-1659.
14. Garseth M, Sonnewald U, White LR, Rod M, Nygaard O, et al. (2002) Metabolic changes in the cerebrospinal fluid of patients with lumbar disc herniation or spinal stenosis. J Neurosci Res 69: 692-695.
15. 1H magnetic resonance spectroscopy in human hydrocephalus. J Magn Reson Imaging 17: 291-299.
16. 1H NMR spectroscopy of cerebrospinal fluid in spinal diseases. Neurosurg Rev 16: 307-315.
17. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom L, et al. (2005) Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 5: 1-6.
18. White LR, Garseth M, Aasly J, Sonnewald U (2004) Cerebrospinal fluid from patients with dementia contains increased amounts of an unknown factor. J Neurosci Res 78: 297-301.
19. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, et al. (2000) Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12: 3721-3728.
20. Wold S, Antti H, Lindgren F, Ohman J (1998) Orthogonal signal correction of near-infrared spectra. Chemometrics Intelligent Lab Systems 44: 175-185.
21. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, et al. (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62: 19-28.
22. Newcomer JW (2004) Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 65: 36-46.
23. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289.
24. Henderson DC, Ettinger ER (2002) Schizophrenia and diabetes. Int Rev Neurobiol 51: 481-501.
25. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, et al. (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65: 1335-1342.
26. Dinan T, Peveler R, Holt R (2004) Understanding schizophrenia and diabetes. Hosp Med 65: 485-488.
27. Elman I, Rott D, Green AI, Langleben DD, Lukas SE, et al. (2004) Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology (Berl) 176: 369-375.
28. Iwamoto K, Bundo M, Kato T (2005) Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 14: 241-253.
29. Karry R, Klein E, Ben Shachar D (2004) Mitochondrial complex I subunits expression is altered in schizophrenia: A postmortem study. Biol Psychiatry 55: 676-684.
30. Pierre K, Pellerin L (2005) Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J Neurochem 94: 1-14.
31. Hawkins RA, Mans AM, Davis DW (1986) Regional ketone body utilization by rat brain in starvation and diabetes. Am J Physiol 250: E169-E178.
32. Fernandes J, Berger R, Smit GP (1982) Lactate as energy source for brain in glucose-6-phosphatase deficient child. Lancet 1: 113.
33. Kammula RG, Fong BC (1973) Metabolism of glucose and acetate by the ovine brain in vivo. Am J Physiol 225: 110-113.
34. Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, et al. (2005) Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A 102: 5221-5226.
35. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW (2001) Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: Evidence for myelin-associated aspartoacylase. J Neurochem 78: 736-745.
36. 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis. Neuropsychopharmacology 30: 1949-1962.
37. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004) . (2004) Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697, 643.
38. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98: 4746-4751.
39. Maillet S, Vion-Dury J, Confort-Gouny S, Nicoli F, Lutz NW, et al. (1998) Experimental protocol for clinical analysis of cerebrospinal fluid by high resolution proton magnetic resonance spectroscopy. Brain Res Brain Res Protoc 3: 123-134.
40. Regenold WT, Phatak P, Kling MA, Hauser P (2004) Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders. Mol Psychiatry 9: 731-733.
41. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, et al. (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59: 921-928.
42. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, et al. (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163: 790-799.